Barclays
MRTX

Barclays’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Barclays’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,500
Closed -$441K – 5479
2023
Q4 		$441K Buy
+7,500
New +$422K ﹤0.01% 3959
2021
Q4 		– Sell
-3,300
Closed -$584K – 4852
2021
Q3 		$584K Buy
+3,300
New +$531K ﹤0.01% 3108
2021
Q1 		– Sell
-200
Closed -$44K – 5310
2020
Q4 		$44K Hold
200
– – ﹤0.01% 4466
2020
Q3 		$33K Hold
200
– – ﹤0.01% 4775
2020
Q2 		$23K Hold
200
– – ﹤0.01% 5175
2020
Q1 		$15K Buy
+200
New +$17.9K ﹤0.01% 5727
2019
Q4 		– Sell
-45,000
Closed -$3.51M – 6943
2019
Q3 		$3.51M Buy
45,000
+20,000
+80% +$1.88M ﹤0.01% 2208
2019
Q2 		$2.58M Sell
25,000
-225,171
-90% -$17.5M ﹤0.01% 2622
2019
Q1 		$18.3M Buy
+250,171
New +$17M 0.01% 896
2018
Q4 		– Sell
-280,000
Closed -$13.2M – 7451
2018
Q3 		$13.2M Buy
280,000
+227,400
+432% +$12.7M 0.01% 1095
2018
Q2 		$2.59M Buy
+52,600
New +$1.99M ﹤0.01% 2321

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's MRTX Position: Q1 2024 in Review

Barclays sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 492,345 shares — an estimated $28.9M sold.

Barclays first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $28.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Barclays reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 492,345 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $28.9M.
  • Barclays first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
  • Barclays's Mirati Therapeutics, Inc. Common Stock position peaked at $28.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.